Humana (NYSE:HUM) PT Raised to $407.00

Humana (NYSE:HUM) had its price target raised by TD Cowen from $396.00 to $407.00 in a report issued on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the insurance provider’s stock.

A number of other equities analysts have also weighed in on HUM. UBS Group cut their price objective on shares of Humana from $334.00 to $326.00 and set a neutral rating for the company in a research report on Thursday, April 25th. Oppenheimer cut their price objective on shares of Humana from $415.00 to $370.00 and set an outperform rating for the company in a research report on Thursday, April 25th. Cantor Fitzgerald reaffirmed a neutral rating and set a $360.00 price target on shares of Humana in a research report on Tuesday, July 23rd. Baird R W raised shares of Humana to a hold rating in a research report on Thursday, May 30th. Finally, Robert W. Baird started coverage on shares of Humana in a research report on Thursday, May 30th. They set a neutral rating and a $374.00 price target for the company. Fourteen investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of Hold and an average target price of $402.60.

Humana Stock Performance

NYSE:HUM opened at $392.63 on Wednesday. The firm has a 50 day simple moving average of $365.66 and a 200-day simple moving average of $347.02. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67. The firm has a market cap of $47.31 billion, a PE ratio of 24.45, a P/E/G ratio of 2.27 and a beta of 0.51. Humana has a 1-year low of $298.61 and a 1-year high of $530.54.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. The business had revenue of $29.61 billion during the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company’s revenue was up 10.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $9.38 earnings per share. On average, equities analysts expect that Humana will post 16.27 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Mendota Financial Group LLC boosted its stake in shares of Humana by 9.2% in the second quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock valued at $119,000 after purchasing an additional 27 shares during the period. Aurora Investment Counsel boosted its stake in shares of Humana by 1.3% in the fourth quarter. Aurora Investment Counsel now owns 2,273 shares of the insurance provider’s stock valued at $1,155,000 after purchasing an additional 29 shares during the period. Signaturefd LLC boosted its stake in shares of Humana by 1.2% in the fourth quarter. Signaturefd LLC now owns 2,634 shares of the insurance provider’s stock valued at $1,206,000 after purchasing an additional 30 shares during the period. Brighton Jones LLC boosted its stake in shares of Humana by 6.8% in the fourth quarter. Brighton Jones LLC now owns 470 shares of the insurance provider’s stock valued at $215,000 after purchasing an additional 30 shares during the period. Finally, Capital Advisors Ltd. LLC boosted its stake in shares of Humana by 17.0% in the second quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock valued at $80,000 after purchasing an additional 31 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.